Mandate

Vinge advises Anyfin in a capital procurement of SEK 450 million

October 05, 2021 M&A

The new financing will be used for future internationalization, among other things, in conjunction with the company’s launch in Germany, and for future investments in technology and in order to broaden the product offering.

Anyfin helps its customers to reduce their interest costs by refinancing original loans and providing better offers in respect of the customers’ loans.

Vinge’s team primarily consisted of Johan Larsson, Carl Sander, Ellinor Wargenbrant, Stina Bengtsson and Eléonore Friberg.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026